Vera Novak, MD, PhD, discusses the research behind this presentation which begins at 8:10 a.m. CT on Tuesday. A livestream and on-demand recording are available at ADA2022.org.

Maria J. Redondo, MD, PhD, MPH, discusses the research behind this presentation which begins at 8:00 a.m. CT on Tuesday. A livestream and on-demand recording are available at ADA2022.org.

Dongyin Guan, PhD, discusses the research behind this presentation which begins at 7:30 a.m. CT on Tuesday. A livestream and on-demand recording are available at ADA2022.org.

Audrey V. Parent, PhD, discusses the research behind this presentation which begins at 5:30 p.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

“What’s unique about these new classes of drugs is that they’re not glucose-lowering drugs. They’re cardio-renal risk-reducing agents that happen to lower glucose if your kidney function is normal or reasonable,” said George Bakris, MD, who will present during the symposium, which begins at 4:30 p.m. CT on Monday.

Cardiovascular disease is recognized as one of the most common complications of diabetes. Clinicians have long viewed coronary arterial disease and atherosclerosis as the major culprits, but heart failure has emerged as a larger problem—and one that’s more difficult to manage, according to Rong Tian, MD, PhD, who will present during a symposium at 4:30 p.m. CT Monday.

Four cardiologists, including Yi Tan, PhD (left), and Harold E. Bays, MD, will discuss the underlying mechanisms, diagnosis, and treatment of cardiomyopathy, a familiar yet underappreciated complication of diabetes during a symposium at 4:30 p.m. CT on Monday. “My sense is we are on the cusp of some really interesting times in cardiomyopathy in diabetes,” Dr. Bays said.

The ADA and the European Association for the Study of Diabetes will release the latest consensus recommendations on managing hyperglycemia in type 2 diabetes during a special joint session beginning at 4:30 p.m. CT on Monday. The symposium will be co-chaired by ADA Chief Scientific and Medical Officer Robert A. Gabbay, MD, PhD, and EASD President Stefano Del Prato, MD.

Julia E. Blanchette, PhD, RN, BC-ADM, CDCES, discusses the research behind this presentation which begins at 3:45 p.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

Vincent Prevot, PhD, discusses the research behind this presentation which begins at 2:45 p.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

Paul McGuigan, RN, discusses the research behind this presentation which begins at 2:15 p.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

In a symposium at 2:15 p.m. CT on Monday, four diabetes care and education specialists, including Paul McGuigan, RN, CDCES, and Julia E. Blanchette, PhD, RN, BC-ADM, CDCES, will discuss both time-tested and novel approaches to improve the quality-of-life of young people living with diabetes.

Amy K. Mottl, MD, MPH, FASN, will open the joint session, which brings together experts from various disciplines in an effort to improve screening, uptake of practice guidelines, and patient outcomes. The symposium begins at 2:15 p.m. on Monday.

Research examining central nervous system control of systemic metabolism suggests that the CNS plays an important, and perhaps a dominant role in the pathogenesis and progression of at least some forms of diabetes. Four leaders in the field, including Vincent Prevot, PhD, and Sarah Stanley, MB, BCh, PhD, will review the latest findings at 2:15 p.m. CT on Monday.

Noel C. Barengo, MD, PhD, MPH, discusses the research behind this presentation which begins at 12:25 p.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

Ebony B. Carter, MD, MPH, discusses the research behind this presentation which begins at 12:05 p.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

Juan R. Alvarez Dominguez, PhD, discusses the research behind this presentation which begins at 9:00 a.m. CT on Monday. A livestream and on-demand recording are available at ADA2022.org.

Lauren B. Beach, JD, PhD, discusses the research behind this presentation which begins at 6:00 p.m. CT on Sunday. A livestream and on-demand recording are available at ADA2022.org.

In a symposium beginning at 4:30 p.m. CT on Sunday, four experts, including Satish K. Garg, MD, and Holly Willis, PhD, RDN, CDCES, will discuss practical strategies to improve eating habits and optimize the growing number of insulin-dosing options to improve glucose control, increase time in range, reduce A1C, and lower the risk of long-term complications from poor glucose control.

Jamie Feldman, MD, will chair a Scientific Sessions symposium at 4:30 p.m. CT on Sunday examining diabetes, metabolic health, and clinical care among people who are lesbian, gay, bisexual, transgender, gender diverse, queer, or questioning.

Diabetic peripheral neuropathy (DPN) remains undertreated, according to Loretta Vileikyte, MD, PhD (left), who will discuss the psychosocial impact of painful DPN during a symposium beginning at 4:30 p.m. CT on Sunday. Stephanie Eid, PhD, will discuss efforts to develop mechanism-based therapies that impact peripheral neuropathy before irreversible nerve damage occurs.

Shahzeb Khan, MD, MSc, discusses the research behind this presentation which begins at 3:45 p.m. CT on Sunday. A livestream and on-demand recording are available at ADA2022.org.

Anna L. Gloyn, DPhil, discusses the research behind this presentation which begins at 3:45 p.m. CT on Sunday. A livestream and on-demand recording are available at ADA2022.org.

“Heart failure has been a forgotten disorder because the basic and translational science models were created with atherosclerosis in diabetes leading to ischemic heart attacks and strokes. But if you look at the real world, people with diabetes develop heart failure and their mortality is horrific,” said Eldrin F. Lewis, MD, MPH, who will be presenting in this symposium, which starts at 2:15 p.m. on Sunday.

Amit R. Majithia, MD, discusses the research behind this presentation which begins at 2:15 p.m. CT on Sunday. A livestream and on-demand recording are available at ADA2022.org.

Jasmine D. Gonzalvo, PharmD, CDCES, BC-ADM, discusses the research behind this presentation which begins at 9:00 a.m. CT on Sunday. A livestream and on-demand recording are available at ADA2022.org.

Anne Peters, MD, discusses the research behind this presentation which begins at 8:00 a.m. CT on Sunday. A livestream and on-demand recording are available at ADA2022.org.

In a symposium at 8:00 a.m. CT on Sunday, June 5, Hollie Raynor, PhD, RD, and three other expert presenters will review the latest lessons learned for maximizing weight loss maintenance in the U.S. National Diabetes Prevention Program.

Linda A. DiMeglio, MD, MPH, David A. D’Alessio, MD, and Silvia Corvera, MD, will summarize a year’s worth of discovery, innovation, and paradigm shifts in diabetes research and care during the annual Year in Review symposium at 8:00 a.m. CT on Sunday.

In a symposium at 8:00 a.m. CT on Sunday, a multidisciplinary panel including diabetes care and education specialists Jasmine D. Gonzalvo, PharmD, CDCES, BC-ADM (left), and Vivian N. Ayuk, PharmD, CDCES, will discuss educational strategies to help underserved populations overcome barriers to technology access.

The ADA and the European Association for the Study of Diabetes published a consensus report on precision diabetes medicine in 2020. Scientific Sessions attendees will get an update on this joint initiative during a special symposium at 4:00 p.m. CT on Saturday. John M. Dennis, PhD, and David Kerr, MD, are two of the featured presenters.

Krista A. Varady, PhD, discusses the research behind this presentation which begins at 4:00 p.m. CT on Saturday. A livestream and on-demand recording are available at ADA2022.org.

Nicolai Jacob Wewer Albrechtsen, MD, PhD, discusses the research behind this presentation which begins at 2:45 p.m. on Saturday. A livestream and on-demand recording are available at ADA2022.org.

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, and Michelle F. Magee, MD, MB, BCh, LRCPSI, will review the updated national standards for diabetes self-management education and support during a symposium at 1:45 p.m. Saturday. A companion session will outline the revised certification program for certified diabetes care and education specialists.

Ildiko Lingvay, MD, MPH, MSCS, discusses the research behind this presentation which begins at 1:45 p.m. CT on Saturday. A livestream and on-demand recording are available at ADA2022.org.

Nuzhat Chalisa, MD, FACE, discusses the research behind this presentation which begins at 11:55 a.m. CT on Saturday. A livestream and on-demand recording are available at ADA2022.org.

Windy Cole, DPM, CWSP, discusses the research behind this presentation which begins at 11:35 a.m. CT on Saturday. A livestream and on-demand recording are available at ADA2022.org.

There’s no shortage of things to do or sights to see in New Orleans. Founded by the French and later ruled by the Spanish, this one-of-a-kind city is jam-packed with European, Southern, Creole, and Cajun influences.

Mohammad S. Kuchay, MD, DM, discusses the research behind this presentation which begins at 9:00 a.m. CT on Saturday. A livestream and on-demand recording are available at ADA2022.org.

Factors such as sex, gender, age, ethnicity, education, and living environment affect a person’s physical activity. Jane E. Yardley, PhD, and three other experts will share strategies for prescribing physical activity that are feasible and sustainable for various patient groups during a symposium at 8:00 a.m. on Saturday.

It’s hard to go wrong dining out in the Big Easy, a city with rich culinary traditions. But if you’re not comfortable leaving things to chance, check out our restaurant recommendations before heading out for a bite.

Laurel H. Messer, PhD, MPH, RN, CDCES, discusses the research behind this presentation which begins at 5:15 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

Katharine R. Barnard-Kelly, PhD, discusses the research behind this presentation which begins at 4:39 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

The mental health burden of diabetes remains “grossly underappreciated,” according to Katharine Barnard, PhD. She and other experts will discuss strategies to identify and provide support to diabetes patients at risk for suicide and self-harm during a symposium at 4:15 p.m. CT on Friday.

Elizabeth Selvin, PhD, MPH, discusses the research behind this presentation which begins at 4:45 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

David Maahs, MD, PhD, discusses the research behind this presentation which begins at 4:45 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

Luis A. Rodriguez, PhD, MPH, RD, discusses the research behind this presentation which begins at 3:12 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

Viral N. Shah, MD, discusses the research behind this presentation which begins at 3:00 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

Two symposia beginning at 2:00 p.m. CT on Friday will review the latest findings and new treatment strategies to mitigate cardiac and kidney disease in diabetes. “Our patients cross the boundaries between cardiology and diabetes, and we have to do the same to co-manage them more effectively,” said Suzanne V. Arnold, MD, MHA.

In a session at 2:00 p.m. CT on Friday, five diabetes researchers, including Luis A. Rodriguez, PhD, MPH, RD, and Deborah A. Ellis, PhD, will discuss how translational science is being used to promote health equity and address social determinants of health in diabetes prevention and care.

Jim Johnson, PhD, discusses the research behind this presentation which begins at 12:45 p.m. CT on Friday. A livestream and on-demand recording are available at ADA2022.org.

The bionic pancreas, a system that mimics the natural pancreatic regulation of serum glucose by automatically dosing insulin and glucagon, has been a dream for decades. New research to be presented in a mini-symposium at 12:45 p.m. CT on Friday could reveal whether that dream is one step closer to reality, according to Roy W. Beck, MD, PhD.

The American Diabetes Association is pulling back the curtain on its annual updates to the ADA Standards of Care in a mini-symposium beginning at 12:45 p.m. CT on Friday. “We will share how we work with new data that have been published recently to adjust the standards,” said Vanita R. Aroda, MD, a member of the ADA Professional Practice Committee.

In a session at 11:30 a.m. CT on Friday, Maureen Chomko, RD, CDCES, and Alison Evert, MS, RDN, CDCES, will help Scientific Sessions attendees clear up confusion about healthy eating habits so they can have quality conversations about nutrition with their patients.

The stage is set for the 82nd Scientific Sessions in New Orleans, with a robust program featuring 139 invited speaker sessions, 370 oral presentations, and more than 1,000 poster and e-poster presentations covering the hottest topics, latest research discoveries, and emerging trends in diabetes research, prevention, and care. Virtual participation is also an option for those unable to travel.

A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin from 10:15 a.m. – 12:15 p.m. ET.

Maryam Afkarian, MD, PhD, will explore some of the challenges to the practical application of tools to manage diabetes and kidney disease in a symposium beginning at 9:00 a.m. ET.

Marcus D. Goncalves, MD, PhD, shares details about this presentation, which begins at 9:30 a.m. ET.

New, detailed results of the first Phase 3 SURPASS clinical trials involving tirzepatide will be presented in a dedicated symposium at 8 a.m. “The glucose-lowering and weight reductions of this dual incretin receptor agonist are unprecedented,” said Julio Rosenstock, MD.

Paul W. Franks, PhD, and Kevin D. Hall, PhD, will present opposing viewpoints about whether the hype about precision nutrition outweighs the science during a debate at 8:00 a.m. ET on the final day of the Scientific Sessions.

Manoj Bhasin, PhD, MS, will unveil some of the latest developments in multi-dimensional and spatial single-cell omics in a session beginning at 8:00 a.m. ET.

Michelle M. Kittleson, MD, PhD, and Nasrien E. Ibrahim, MD, will discuss how recent trial results can be leveraged to save lives with angiotensin receptor-neprilysin inhibition and SGLT2 inhibitors. The session begins at 8:00 ET.

Lorenzo Pasquali, MD, PhD, shares details about this presentation, which begins at 9:00 a.m. ET.

Guoxun Chen, PhD, shares details about this presentation, which begins at 4:30 p.m. ET.

Maureen Monaghan, PhD, CDCES, Samantha Kleinberg, PhD, and Jennifer Raymond, MD, MCR, will offer insight into navigating the diabetes digital landscape in a symposium at at 4:30 p.m. ET.

“We hope to give clinicians a comprehensive, comparative view of which drugs do what and in which people,” said GRADE Principal Investigator David Nathan, MD. “It’s about time that we started to find out how these different drugs act in different populations.” GRADE results will be presented at 4:30 p.m. ET.

At 2:15 p.m. ET, Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.

Kelly M. Rawlings, MS, and Marci Butcher, RD, LN, CDCES, FADCES, will discuss digital health and diabetes support in a two-hour symposium at 2:15 p.m. ET.

Carlos A. Monteiro, MD, PhD, will share data on the effects of ultraprocessed foods, while Sung Kyun Park, ScD, MPH, will provide data on per- and polyfluoroalkyl substances in a symposium that begins at 2:15 p.m. ET.

At 2:15 p.m. ET, a joint symposium of the ADA and the International Society for Pediatric and Adolescent Diabetes featuring Richard A. Oram, MD, PhD, and R. Brett McQueen, PhD, will consider general population screening versus targeted screening.

Raghavendra Rao, MD, Charles Stanley, MD, Sarbattama Sen, MD, and Paul Rozance, MD, will address whether neonatal hypoglycemia is overdiagnosed or underestimated in this symposium that begins at 2:15 p.m. ET.

An expert panel including Kathryn Haskins, PhD, Teresa P. DiLorenzo, PhD, and Megan K. Levins, PhD, will discuss the past, present, and future of T cells in diabetes treatment in a symposium starting at 2:15 p.m. ET.

Rajesh Garg, MD, shares details about this presentation, which begins at 12:20 p.m. ET.

Rana K. Gupta, PhD, shares details about this presentation, which begins at 9:30 a.m. ET.

Joseph Aloi, MD, shares details about this presentation, which begins at 9:36 a.m. ET.

Foluso A. Fakorede, MD, shares details about this presentation, which begins at 9:30 a.m. ET.

Guoqiang Gu, PhD, shares details about this presentation, which begins at 8:30 a.m. ET.

The data from continuous glucose monitoring devices can help patients make more informed decisions on lifestyle modifications, insulin dosing, and meal planning. Thomas W. Martens, MD, Dana Gershenoff, MS, RD, CDCES, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, explain how in a session at 8:00 a.m. ET.

Richard I.G. Holt, PhD, FRCP, and Anne L. Peters, MD, and their writing team will summarize the key topics addressed by this trans-Atlantic collaboration. The session, beginning at 8:00 a.m. ET, will include a live video question and answer period.

Catlin Dennis, MPH, Gretchen Piatt, PhD, MPH, Christine H. Wang, PhD, and Sarah Westen, PhD, will come together in a 4:30 p.m. ET session to help quantify the toll the COVID-19 pandemic has taken on diabetes patients and their families.

Dudley Lamming, PhD, shares details about this presentation, which begins at 4:54 p.m. ET.

Data support the use of telehealth and remote monitoring for patients with diabetes. Leslie A. Eiland, MD, Lindsay S. Mayberry, PhD, MS, and Irl B. Hirsch, MD, will outline how to use these tools for different populations in a session beginning at 4:30 p.m. ET.

The symposium will include a review of treatment options for preproliferative diabetic retinopathy by Jennifer Sun, MD, MPH, and an overview of advancements in retinal neurovascular degeneration in diabetes by Patrice E. Fort, PhD, MS. The session begins at 4:30 p.m. ET.

The Year in Review, from 4:30 p.m. – 6:30 p.m. ET, offers a broad look at advancements in basic, clinical, and translational sciences, putting into context recent research and the future of the field. Speakers include Maureen Gannon, PhD, and Jay S. Skyler, MD, MACP.

Sachin D. Shah, MD, shares details about this presentation, which begins at 3:45 p.m. ET.

DARE-19 Principal Investigator Mikhail Kosiborod, MD, will provide the first look at a subgroup analysis of type 2 diabetes patients who are at higher risk for developing serious complications from COVID-19 in a session beginning at 2:15 p.m. ET.

Leonard E. Egede, MD, MS, shared details about this presentation, which begins at 2:55 p.m. ET.

Bobeck Modjtahedi, MD, shared details about this presentation, which begins at 12:35 p.m. ET.

“The understanding of energy metabolism and its relation to diabetes and obesity is undergoing a revolution,” said Bruce Spiegelman, PhD, one of the researchers who will discuss emerging paradigms of uncoupled bioenergentics in metabolic disease at 8:00 a.m. ET.

Maisa N. Feghali, MD, Randi Streisand, PhD, CDCES, and Jessica Pierce, PhD, will outline how the strategies providers use to promote positive mental health for their patients living with diabetes must evolve as their patients mature. A two-hour session on preserving mental health throughout the lifespan of people with diabetes will begin at 8:00 a.m. ET.

Makoto Fukuda, PhD, and Tune H. Pers, PhD, will discuss GIP signaling in the brain and its effects on food intake and energy balance at 8:00 a.m. ET as part of this year’s ADA Diabetes Symposium.

In a two-hour symposium on developing a more stratified medical approach from the bench to bedside, Emilyn Uy Alejandro, PhD, and Rochelle N. Naylor, MD, will discuss new insights into the heterogeneity of diabetes and how it translates to patient care. The session begins at 4:00 p.m. ET.

Clemence Frerebeau, PhD, shared details about this presentation, which begins at 5:00 p.m. ET.

Yehuda Handelsman, MD, Tina Costacou, PhD, and Sophia Zoungas, MBBS (Hons), PhD, FRACP, will examine the dynamics of weight and cardiovascular risk in type 1 diabetes. The symposium, starting at 4:00 p.m. ET, includes a debate on drugs to prevent cardiovascular disease.

“You could eat a diet of bacon and diet soda all day long and you’d manage your glucose really well. But that wouldn’t be good for your whole health,” said Holly Willis, PhD, RDN, LD. She is part of an expert panel that will discuss the interplay of new technology and advances in the understanding of nutrients’ effects on blood glucose in a two-hour symposium beginning at 4:00 p.m.

Kavita Singh, PhD, shared details about this presentation, which begins at 4:30 p.m. ET.

Inês Barroso, PhD, shared details about this presentation, which begins Saturday, June 26, at 2:15 p.m. ET.

Jeffrey R. Millman, PhD, shared details about this presentation, which begins at 1:45 p.m. ET.

The digital diabetes care market will be worth upward of $700 million in 2022. Anne L. Peters, MD, and Kasia J. Lipska, MD, MHS, BS, will explore whether it is worth the cost in a debate at 1:45 p.m. ET.

In 1921, the discovery of insulin transformed type 1 diabetes from a death sentence. In a special session starting at 1:45 p.m. ET, experts including Peter Arvan, MD, PhD, and Michael A. Weiss, MD, PhD, MBA, will explore the ramifications of this critical inflection point in medicine.

In a session starting at 1:45 p.m. ET Jennifer Sherr, MD, PhD, will highlight new glucagon formulations for treatment, and Nicole de Zoysa, DClinPsych, will review the impact of overcoming psychological obstacles on optimal hypoglycemia management.

The average ages of patients who are potentially eligible for pancreas transplantation and of potential organ donors are on the rise, but that is not the only challenge for this sector of the diabetes community, as Eelco J.P. de Koning, MD, PhD, will explain in a session beginning at 1:45 p.m. ET.

The 2021 Diabetes Care Symposium, featuring speakers Matthew C. Riddle, MD, and Paresh Dandona, MD, PhD, is examining how to mitigate the threefold risk for severe COVID-19 infection among diabetes patients until 10:00 a.m. ET.

Veterans and active-duty military personnel with diabetes can now receive self-management education in a simulated environment. The ADA Education Recognition Program Symposium, from 8:00 a.m. – 10:00 a.m. ET, features a panel of speakers involved in the development of the Virtual Medical Center and new training offered there by the U.S. Department of Veterans Affairs.

Muthiah Vaduganathan, MD, MPH, shares details about this presentation, which begins at 8:30 a.m. ET.

Florin Despa, PhD, shared details about this presentation, which begins at 8:30 a.m. ET.

Ananta Addala, DO, MPH, shared details about this presentation, which begins at 8:25 a.m. ET.

In a symposium beginning at 4:15 p.m. ET, Hui Shao, MD, PhD, will discuss the financial implications on the health care system brought by these classes of agents, which have transformed diabetes care for individuals who also have cardiovascular disease.

Shivani Agarwal, MD, MPH, Shakira Suglia, ScD, MS, and J. Frank Wharam, MD, MPH, will examine strategies to address risks influenced by social needs and to improve outcomes in a session beginning at 2:00 p.m. ET.

The diabetes community moved quickly to understand and counter the deadly dynamics of COVID-19 and hyperglycemia. Alberto Coppelli, MD, and Francisco J. Pasquel, MD, MPH, will provide a view from the frontlines in a symposium at 2:00 p.m. ET.

In a session starting at 12:45 p.m. ET, Jennifer Green, MD, will discuss some of the factors that may give clinicians second thoughts about initiating these two classes of drugs.

Amir Moheet, MBBS, shared details about this presentation, which begins at 1:15 p.m. ET.

“The relationship between viruses, genetic background, and the immune system are all involved in this autoimmune process that leads to disease,” explained epidemiologist Kendra Vehik, PhD, MPH, one of the featured speakers for a mini-symposium starting at 12:45 p.m. ET.

Carol A. Shively, PhD, shared details about this presentation, which begins at 1:05 p.m. ET.

Jennifer LeBlanc, CDCES, shared details about this presentation, which begins at 12:00 p.m. ET.

The first 4,000 U.S. attendees to register for the meeting will receive a Welcome Box delivered to their designated mailing address prior to the start of the meeting. Each box will include promotional items to add exciting physical elements to the virtual program.

Five experts reviewed critical lessons from two decades of surveillance and observational research into youth-onset diabetes during a two-hour virtual symposium at the Scientific Sessions. The expert presenters, including symposium chair Dana Dabelea, MD, PhD, are key participants in the SEARCH for Diabetes in Youth Study, a national multi-center study with centers in California, Colorado, Ohio, South Carolina, and Washington.

During a virtual symposium at the Scientific Sessions, three experts discussed challenges faced by young adults with type 1 diabetes as they make the transition from childhood to adulthood. The panelists, including Anna Floreen Sabino, MSW, CDCES, emphasized the importance of strong support systems and access to helpful resources.

During the Scientific Sessions, Scott A. Summers, PhD, reviewed the strong association of serum ceramides with insulin resistance and major adverse cardiac events. He also discussed new therapeutic approaches to lower ceramides and combat diabetes and its comorbidities.

Bruce A. Buckingham, MD, and three other experts reviewed results from four new clinical trials examining the next generation of automated insulin delivery systems for type 1 diabetes patients during the Scientific Sessions. New technology holds promise for easing the lifestyle complications of type 1 diabetes by improving glycemic control, particularly overnight, Dr. Buckingham said.

Three distinguished presenters reviewed some of the most significant advances in diabetes during the Year in Review symposium, one of the most popular presentations each year at the Scientific Sessions. Alan Saltiel, PhD, reviewed basic science highlights while Lora K. Heisler, PhD, focused on translational science and David M. Nathan, MD, revisited clinical science highlights from the past year.

Gretchen Benson, RDN, CDCES, discussed how a team-based approach featuring an expanded role for registered dietitian nutritionists (RDN) can help patients with type 2 diabetes, hypertension, and hyperlipidemia achieve better outcomes. She highlighted results from several studies demonstrating the benefits of expanding the role of RDNs in initiating/titrating medications.

The Restoring Insulin Secretion (RISE) Study, which tested interventions designed to preserve or improve beta-cell function in prediabetes and early type 2 diabetes, offers important insight into differences between adults and youth in the onset and progression of type 2 diabetes. Given the differences in the two populations, investigators like Kristen Nadeau, MD, MS, are looking closely at the RISE data to see if the differences can be explained.

During the ninth annual Diabetes Care Symposium, a panel of world-renowned clinicians and researchers emphasized the need to consider all aspects of diabetes over long periods of time rather than relying on short-term clinical studies, single clinical assessments of patients, and short-term therapeutic goals. Diabetes Care Editor in Chief Matthew C. Riddle, MD, moderated the symposium.

Emma E. Hamilton-Williams, PhD, described results from the TOGeTHER Trial of type 1 diabetes patients, who were treated with a specially modified dietary fiber designed to deliver short-chain fatty acids into the large intestine. Her presentation details the impact of the supplement on the gut bacteria and the diabetes management of trial participants, revealing a promising new avenue for type 1 diabetes therapy.

Results from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) showed that dapagliflozin, an SGLT2 inhibitor, reduced the incidence of type 2 diabetes by 32% in patients with heart failure but without diabetes at baseline. “While the major role of dapagliflozin is to reduce cardiovascular mortality and worsening of heart failure, decreasing incident diabetes could be considered an additional benefit,” said Silvio E. Inzucchi, MD.

Elizabeth Selvin, PhD, MPH, the 2020 recipient of the Kelly West Award for Outstanding Achievement in Epidemiology, reviewed highlights from decades of epidemiological evidence supporting the use of A1C for the management and diagnosis of diabetes during her Scientific Sessions award lecture. She also addressed recent controversies and criticism of the biomarker’s limitations.

The International Hypoglycemia Study Group recently proposed a revised classification of hypoglycemia that has been adopted by the ADA, the European Association for the Study of Diabetes, and a number of other organizations. Simon R. Heller, MD, FRCP, discusses the rationale behind the IHSG’s proposed definitions, how these definitions have impacted current guidelines, and what steps still need to be taken to adopt a universal hypoglycemia definition.

Investigators from The Environmental Determinants of Diabetes in the Young (TEDDY) study presented the latest results from the ongoing study during the Scientific Sessions. TEDDY Co-Chair Marian Rewers, MD, PhD, reviewed research into genetic and clinical markers that indicates that screening for islet autoimmunity in high-risk youth should start in the first two years of life. He also reviewed data on potential environmental triggers of islet autoimmunity, including viral infections and the gut microbiome.

Ongoing research into the mechanisms of inter-organ crosstalk, including the key signaling pathways involved in obesity and diabetes, may provide targets for new therapies to treat, and potentially even prevent, these and other metabolic disorders, according to Jiandie Lin, PhD, recipient of the 2020 ADA Outstanding Scientific Achievement Award.

Marisa E. Hilliard, PhD, discussed the concept of integrating positive psychology approaches into diabetes interventions during the Scientific Sessions. She presented research on intervention strategies designed to promote resilience in teens with diabetes by targeting family and health care systems.

Findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, one of the newer sodium-glucose cotransporter 2 (SGLT2) inhibitors, indicate that the drug does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes. The findings were presented by a panel of the trial investigators, including Christopher P. Cannon, MD, during the Scientific Sessions.

William H. Polonsky, PhD, CDE, ADA’s 2020 Outstanding Educator in Diabetes, told viewers of his Scientific Sessions award lecture that he would attempt to discuss boredom without being boring. “I’m not sure I can pull it off,” he said. But based on comments from virtual attendees, not only did he pull it off, he also inspired many to re-examine their Diabetes Self-Management Education and Support programs to improve efficacy.

Feyza Engin, PhD, discussed beta-cell endoplasmic reticulum stress in type 1 diabetes during the Scientific Sessions. Although immune dysregulation plays a vital role in type 1 diabetes pathogenesis, emerging data suggest that beta cells are not passive bystanders but play an active role in their own demise, she said.

Several researchers from the Diabetes Prevention Program Outcomes Study (DPPOS), including DPPOS Chair David M. Nathan, MD, shared new data on clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program study during the Scientific Sessions.

From working to unravel the mysteries of insulin resistance to exploring the beneficial impact of bariatric surgery, and much more in between, Ele Ferrannini, MD, has made seminal contributions to the understanding of the pathogenesis of type 2 diabetes and its related comorbidities.

Richard E. Pratley, MD, reports the first data on oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

Behavior is the heart of every diabetes intervention, according to Mary de Groot, PhD, HSPP, ADA President, Health Care & Education. “As I share with my patients, medications only work if we take them internally. Devices only work if we use them. The time has come to recognize and celebrate the foundational role that behavior plays in all aspects of diabetes,” Dr. de Groot said.

Robert H. Eckel, MD, ADA President, Medicine & Science, worked with a colleague to design a training program for a new medical subspecialty to address the growing prevalence of obesity, metabolic syndrome, and type 2 diabetes. The program draws on components of preventive cardiology, metabolic aspects of endocrinology, hepatology, nephrology, and lifestyle and obesity medicine.

Matthew J. Budoff, MD, previews his Scientific Sessions presentation examing the use of coronary artery calcium (CAC) scoring in clinical practice. CAC is associated with improved motivation and adherence to therapies. Dr. Budoff examines the evidence for appropriate use of the test.

Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, will be presented at 10:15 a.m. CT by a panel of trial investigators. Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee, will present cardiovascular and renal outcomes from the trial.

The latest clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program study will be presented at 8:00 a.m. CT. The current phase of the Diabetes Prevention Program Outcomes Study is scheduled to run through 2021 and is examining the long-term effects of metformin on cardiovascular disease and cancer outcomes, according to DPPOS Chair David M. Nathan, MD.

During a unique, two-hour Current Issues presentation Tuesday morning, three experts will debate whether microvascular and macrovascular complications of diabetes are distinct pathophysiologic entities. Deborah J. Wexler, MD, MSc, will present an endocrinologist’s perspective and Jasper Tromp, MD, PhD, will offer a cardiologist’s perspective.

Three researchers from Type 1 Diabetes TrialNet—Diane K. Wherrett, MD, FRCPC, S. Alice Long, PhD, and Laura M. Jacobsen, MD—will review the latest research on immune therapy for type 1 diabetes during a two-hour virtual symposium Tuesday morning. TrialNet is an international network of academic institutions, endocrinologists, physicians, scientists, and health care teams dedicated to type 1 diabetes research.

Mounting evidence indicates that sleep loss or insufficient sleep may have ramifications for the diabetes community—affecting patients whether they have type 1, type 2, or are at risk for developing diabetes. Five investigators, including Sarah S. Jaser, PhD, Erin C. Hanlon, PhD, and Susana R. Patton, PhD, will review the latest sleep science and its implications for diabetes patients during a Tuesday morning symposium.